Z Radical Contains Carbon To Carbon Unsaturation Patents (Class 514/549)
  • Patent number: 10322213
    Abstract: Disclosed herein is the correlation of chemical properties of oils with the physical properties of a resulting cured oil composition. Also disclosed are biocompatible materials and coatings for medical devices prepared using enriched oils and methods for enhancing or modifying the physical and chemical characteristics of cured oils by enriching such oils with fatty acid alkyl esters. Methods of tailoring the properties of biocompatible materials and coatings to deliver one or more therapeutic agents are also provided.
    Type: Grant
    Filed: July 16, 2011
    Date of Patent: June 18, 2019
    Assignee: ATRIUM MEDICAL CORPORATION
    Inventors: Keith M. Faucher, Theresa K. Albergo, Paul Martakos
  • Patent number: 10278939
    Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: May 7, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Paresh Soni
  • Patent number: 10265287
    Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: April 23, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 10258594
    Abstract: Disclosed is a semiochemical composition including methyl palmitate, methyl linoleate, methyl oleate methyl stearate, methyl laurate, methyl myristate, salts thereof, derivatives thereof, isomers thereof and/or structural analogues thereof that have an appeasing effect in cats and/or also effects social facilitation in cats, and an acceptable vehicle. Solutions such as spot-on formulations of long duration are also encompassed. Methods to effect appeasing in a cat and/or social facilitation in cats are also disclosed.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: April 16, 2019
    Assignee: INSTITUT DE RECHERCHE EN SEMIOCHIMIE ET ETHOLOGIE APPLIQUEE
    Inventor: Patrick Pageat
  • Patent number: 10239850
    Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: March 26, 2019
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. Serhan, Rong Yang
  • Patent number: 10233168
    Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: March 19, 2019
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. Serhan, Rong Yang
  • Patent number: 10233167
    Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: March 19, 2019
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. Serhan, Rong Yang
  • Patent number: 10227291
    Abstract: The invention describes novel mono or dihydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: March 12, 2019
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Charles N. Serhan, Rong Yang
  • Patent number: 10206898
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent obesity.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: February 19, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Joseph S. Zakrzewski
  • Patent number: 10188625
    Abstract: The present invention concerns a combination of a retinoid and a diol and polyunsaturated fatty acid ester, a dermatological or dermocosmetic composition containing such a combination and use of same in the treatment of acne and the prevention of retentional lesions. The present invention also concerns a retinoid, optionally in combination with a diol and polyunsaturated fatty acid ester, for use in the prevention of retentional lesions.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: January 29, 2019
    Assignee: PIERRE FABRE DERMO-COSMETIQUE
    Inventors: Nathalie Castex-Rizzi, Daniel Redoules, Sandrine Bessou-Touya, Jean-Hilaire Saurat
  • Patent number: 10117844
    Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: November 6, 2018
    Assignees: Omthera Pharmaceuticals, Inc., Chrysalis Pharma AG
    Inventors: Timothy J. Maines, Bernardus N. Machielse, Bharat M. Mehta, Gerald L. Wisler, Michael H. Davidson, Peter Ralph Wood
  • Patent number: 10076550
    Abstract: The present invention relates to a mainly herbal composition comprising Terminalia bellerica fruits (1-5% w/w) more particularly the extract of dried fruits. The composition further has exogenously added malonic acid, glutamic acid, eicosenoic acid and linolenic acid. The composition of present invention is useful in treatment and control of gastro intestinal problems like diarrhea, dysentery, ulcers etc. and used as an oral dosage form.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: September 18, 2018
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Garima Pandey, Chandana Venkateswara Rao, Om Prakash Sidhu, Ajay Kumar Singh Rawat, Chandra Shekhar Nautiyal
  • Patent number: 10058528
    Abstract: Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatis (NASH).
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: August 28, 2018
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Kiyoshi Mizuguchi, Tsuyoshi Harada, Atsushi Osada, Hiroyuki Kawano, Masayuki Ichioka
  • Patent number: 10052299
    Abstract: Some aspects of the invention provide for essential fatty acids which are substituted in specific positions to slow down oxidative damage by Reactive Oxygen Species (ROS), and to suppress the rate of consequent formation of reactive products, for the purpose of preventing or reducing the damage associated with oxidative stress associated diseases such as neurological diseases and age-related macular degeneration (AMD).
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: August 21, 2018
    Assignee: Retrotope, Inc.
    Inventor: Mikhail S. Shchepinov
  • Patent number: 9980934
    Abstract: In an embodiment, compositions comprising monoacylglycerols (MAG), such as sn-1(3) MAG, are administered with a lipase inhibitor, such as tetrahydrolipstatin, and/or with a diet low in fat and/or calories. In another embodiment, compositions comprising MAG, such as sn-1(3) MAG, are administered concurrently with a lipase inhibitor, such as tetrahydrolipstatin, and/or with fat-soluble nutrients. The compositions and the methods of using the compositions enhance absorption of fatty acids and fat-soluble nutrients such as fat-soluble vitamins and carotenoids to address nutritional deficiencies due to a weight loss diet used in association with a lipase inhibitor.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: May 29, 2018
    Assignee: Nestec S.A.
    Inventors: Cristina Cruz-Hernandez, Claudia Roessle, Lada Frolova
  • Patent number: 9925165
    Abstract: There are provided compositions comprising Such compositions can also further comprise various components such as lipids (for example fatty acids, esters thereof or derivatives thereof). Such compositions can be used for example in methods for treating an inflammatory diseases chosen from inflammatory bowel diseases, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, acute lung injury, bronchopulmonary dysplasia, cystic fibrosis, bronchitis, bronchiolitis, arthritis, osteoarthritis, ankylosing spondylitis and rheumatism.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: March 27, 2018
    Assignee: SCF Pharma Inc.
    Inventor: Samuel Fortin
  • Patent number: 9918994
    Abstract: Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: March 20, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Andrew Tri Van Ho, Adelaida R. Palla
  • Patent number: 9918953
    Abstract: Provided are: an eicosapentaenoic acid alkyl ester-ontaining composition which comprises 96-99 area % of an eicosapentaenoic acid alkyl ester, wherein the content of an arachidonic acid alkyl ester is 0.7 area % or less, and the content of mono-trans forms of the eicosapentaenoic acid alkyl ester is 2.5 area % or less; a method for producing a high-concentration eicosapentaenoic acid alkyl ester-containing composition, which comprises performing rectification on an eicosapentaenoic acid alkyl ester-containing composition with the degree of vacuum being 0.2 Torr or less and at a whole-column temperature 190° C. or less, and performing a concentration treatment on the rectified composition using chromatography, the eicosapentaenoic acid alkyl ester-containing composition being obtained by alkyl esterifying a feed oil containing eicosapentaenoic acid.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: March 20, 2018
    Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
  • Patent number: 9895332
    Abstract: Described herein are pharmaceutical compositions comprising polyunsaturated fatty acids and methods of manufacturing the same. In particular, described herein are pharmaceutical compositions comprising soft enteric capsules comprising omega-3 polyunsaturated fatty acids. The oral pharmaceutical compositions described herein are useful as nutritional supplements or for the treatment of cardiovascular-related diseases, such as hyper dyslipidemia and high triglyceride levels.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: February 20, 2018
    Assignee: Patheon Softgels, Inc.
    Inventors: Peijin Zhang, Aqeel A. Fatmi
  • Patent number: 9895333
    Abstract: Described herein are pharmaceutical compositions providing enhanced bioavailability of polyunsaturated fatty acids and methods of manufacturing the same. In particular, described herein are pharmaceutical compositions comprising soft enteric capsules that provide enhanced bioavailability of omega-3 polyunsaturated fatty acids. The oral pharmaceutical compositions described herein are useful as nutritional supplements or for the treatment of cardiovascular-related diseases, such as hyper dyslipidemia and moderate to high triglyceride levels.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: February 20, 2018
    Assignee: Patheon Softgels Inc.
    Inventors: Peijin Zhang, Aqeel A. Fatmi
  • Patent number: 9801846
    Abstract: Described herein are compositions for parenteral administration that include an aqueous phase and 5 to 30%, by weight, of an oil phase, based on the total weight of the composition. The oil phase comprises the omega-3 fatty acid ethylesters eicosapentaenoic acid ethylester, docosahexaenoic acid ethylester, and mixtures thereof. The composition further comprises at least one anionic surfactant and at least one amphoteric surfactant, and less than 0.05% by weight of oleic acid, based on the total weight of the composition. Also described is a method for preparing such a composition as well as such compositions for use as a medicament, in particular for use in treating stroke, sepsis, Alzheimer's disease or cancer. Also featured are methods of treating these conditions by parenterally administering a composition to a patient in need thereof and methods of providing parenteral nutrition to such patients by administering to them a composition as described herein.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: October 31, 2017
    Assignee: Fresenius Kabi Deutchland GmbH
    Inventors: Edmundo Brito De La Fuente, Crispulo Gallegos-Montes, Lida A. Quinchia-Bustamente
  • Patent number: 9782379
    Abstract: The present invention provides a method for the stimulation of secretion or expression of muscular IL-6 in a subject with the administration of Protectin DX (PDX). Particularly, the increase in circulating levels of IL-6 originating from the subject muscles is useful for regulating blood glucose and suppressing lipid-induced inflammation and other related inflammatory conditions such as insulin resistance, metabolic syndrome, type-2 diabetes, hypertension and cardiovascular diseases. Alternatively, the increase in muscular IL-6 expression in a subject may also be useful for increasing energy supply during exercise, or facilitating muscular recovery after strenuous effort.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: October 10, 2017
    Assignee: Universite Laval
    Inventors: Andre Marette, Philip J. White
  • Patent number: 9675696
    Abstract: A method and kits thereof for increasing the efficiency of anti-adhesive compositions by parenterally administering a composition comprising an effective amount of at least one pharmaceutically-acceptable anti-adhesive non-ionic polymer to a site of injury, controlling inflammation at the site of injury, and reducing pain.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: June 13, 2017
    Assignee: Warsaw Orthopedic, Inc.
    Inventor: Kathy L. Chamness
  • Patent number: 9629821
    Abstract: The present invention is based on the discovery that parenteral nutrition (PN) induced liver disease, e.g. fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with PN rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty acid. Thus, the present invention provides a method for treating or preventing liver disease in a human patient obtaining nutritional support through PN. The method comprises intravenous administration of an effective amount of an omega-3-fatty acid emulsion to the patient, wherein the patient is not administered phytosterols or plant derived fatty acids, e.g. omega-6 fatty acids derived from a plant source, and wherein the administration of the omega-3-fatty acid emulsion to the patient is for a period greater than three weeks. Preferably, the administration is for a period of greater than six weeks.
    Type: Grant
    Filed: July 1, 2008
    Date of Patent: April 25, 2017
    Assignee: Childrens Medical Center Corporation
    Inventors: Mark Puder, Kathleen M. Gura
  • Patent number: 9610302
    Abstract: Described herein are manufactured dietary supplements that contain a phospholipid extract and the extract contains two forms of phospholipid-docosahexanoic acid. One form of phospholipid-docosahexanoic acid is phosphatidylcholine-docosahexanoic acid, and another form of phospholipid-docosahexanoic acid is phosphatidylethanolamine-docosahexanoic acid. The manufactured dietary supplement also contains L-methylfolate, vitamin B6, and vitamin B12.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: April 4, 2017
    Assignee: Buriva, LLC.
    Inventors: Brett B. Bartel, Rhett Sean Daniels
  • Patent number: 9549937
    Abstract: Described herein are manufactured dietary supplements that contain a phospholipid extract and the extract contains two forms of phospholipid-docosahexanoic acid. One form of phospholipid-docosahexanoic acid is phosphatidylcholine-docosahexanoic acid, and another form of phospholipid-docosahexanoic acid is phosphatidylethanolamine-docosahexanoic acid. The manufactured dietary supplement also contains L-methylfolate.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: January 24, 2017
    Assignee: Burvia, LLC.
    Inventors: Brett B. Bartel, Rhett Sean Daniels
  • Patent number: 9468620
    Abstract: The present invention relates to use of DHA analogs and their pharmaceutical compositions for treating ototoxicity, by administering these compounds or pharmaceutical compositions to subjects in need thereof. Ototoxicity is defined as damage to the structures of the ear, such as the cochlea and vestibular system, by drugs or toxins. Ototoxicity can result in irreversible hearing loss, tinnitus, dysequilibrium, Meniere's disease, or vertigo.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: October 18, 2016
    Assignee: Andida Pharma, Inc.
    Inventor: Per Gjorstrup
  • Patent number: 9447020
    Abstract: There are provided compounds of formula (I): wherein X1 is O, NH, or S; X2 is O, NH, or S; and X3 is O, NH, or S; and wherein R, R1, T1 and T2 can represent various entities. Such compounds can be useful, for example, for preventing, palliating or treating various diseases such as heart diseases, respiratory diseases, treating inflammatory abnormalities, metabolic disorders or diabetes.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: September 20, 2016
    Assignee: SCF PHARMA INC.
    Inventor: Samuel C. Fortin
  • Patent number: 9446013
    Abstract: Embodiments of the invention comprise methods of reducing circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 and circulating Myeloperoxidase levels by administering to subjects an effective amount of a dietary oil composition containing 20-90 wt % polyunsaturated fatty acids. Lowering oxidized low density lipoprotein-beta-2-glycoprotein complex and Myeloperoxidase levels may be an effective treatment of atherosclerosis.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: September 20, 2016
    Inventor: Bomi Patel Framroze
  • Patent number: 9416118
    Abstract: The invention describes novel mono or dihydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: August 16, 2016
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. Serhan, Rong Yang
  • Patent number: 9364454
    Abstract: The invention describes novel isolated, purified, 10,17-dihydroxy-docosahexaenoic acids, esters, derivatives and their preparation.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: June 14, 2016
    Assignees: The Brigham and Women's Hospital, Inc., University of Southern California
    Inventors: Charles N. Serhan, Nicos A. Petasis, Bruce D. Levy
  • Patent number: 9358293
    Abstract: A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: June 7, 2016
    Assignee: Phoenix Biotechnology, Inc.
    Inventors: Otis C. Addington, Robert A. Newman
  • Patent number: 9326507
    Abstract: A composition and method for treating a Varroa mite infestation using a sexual pheromone for disrupting the mating behavior of the Varroa mite. Additionally, a pesticide for applying to a mating place of the Varroa mite for disrupting the mating behavior of the Varroa mite.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: May 3, 2016
    Assignee: Universitaet Hohenheim
    Inventors: Bettina Ziegelmann, Peter Rosenkranz
  • Patent number: 9265745
    Abstract: The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: February 23, 2016
    Assignee: Brudy Technology S.L.
    Inventors: Joan Carles Domingo Pedrol, Jose Antonio Villegas Garcia
  • Patent number: 9259408
    Abstract: The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 16, 2016
    Assignee: Brudy Technology S.L.
    Inventors: Joan Carles Domingo Pedrol, Jose Antonio Villegas Garcia
  • Patent number: 9220778
    Abstract: A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: December 29, 2015
    Assignee: Phoenix Biotechnology, Inc.
    Inventors: Otis C. Addington, Robert A. Newman
  • Patent number: 9132112
    Abstract: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: September 15, 2015
    Assignee: CHYSALIS PHARMA AG
    Inventors: Jean-Pierre Sachetto, Roly Bufton, Thomas Buser
  • Patent number: 9089483
    Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: July 28, 2015
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hirosato Fujii, Motoo Yamagata
  • Publication number: 20150141510
    Abstract: The present invention provides the following: a cardiovascular disease primary prevention agent, which comprises as the active ingredient at least one selected from the group consisting of EPA, salts thereof, and esters thereof and is for lowering the risk of cardiovascular disease by administration to subjects having a blood (serum or plasma) hs-CRP level of 1.0 mg/L or higher in spite of no history of cardiovascular disease; a combination marker comprising the blood hs-CRP value and serum EPA/AA ratio for evaluating the primary risk of cardiovascular disease in subjects having no history of cardiovascular disease; and a method for extracting subjects with high risk of cardiovascular disease and/or a method for preventing cardiovascular disease.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 21, 2015
    Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Yutaka Kiyohara, Toshiharu Ninomiya, Takashi Yano
  • Patent number: 9034923
    Abstract: The present invention relates to the treatment of Senile Dementia of the Alzheimer's Type (SDAT) by administering to the patient and effective amount of 1-alkyl, 2-acyl-glycerol.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: May 19, 2015
    Assignee: Phenomenome Discoveries Inc.
    Inventor: Dayan Burke Goodenowe
  • Publication number: 20150133408
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of motor neurone disease, diabetic neuropathy, postherpetic neuralgia, acute opioid withdrawal management, obsessive-compulsive disorder, premature ejaculation, PTSD, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, bipolar depression, depression, stress, cancer pain and lower back pain.
    Type: Application
    Filed: February 16, 2013
    Publication date: May 14, 2015
    Inventor: Mahesh KANDULA
  • Publication number: 20150132389
    Abstract: Described herein are compositions including at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions.
    Type: Application
    Filed: December 22, 2014
    Publication date: May 14, 2015
    Inventors: Frederick Sancilio, Peter Persicaner, Janice Cacace, Mohand Dahim
  • Publication number: 20150125529
    Abstract: Described herein are compositions including at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions.
    Type: Application
    Filed: December 22, 2014
    Publication date: May 7, 2015
    Inventors: Frederick Sancilio, Peter Persicaner, Janice Cacace, Mohand Dahim
  • Publication number: 20150125530
    Abstract: Described herein are compositions including at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions.
    Type: Application
    Filed: December 22, 2014
    Publication date: May 7, 2015
    Inventors: Frederick Sancilio, Peter Persicaner, Janice Cacace, Mohand Dahim
  • Publication number: 20150126601
    Abstract: Liquid compositions comprising suspended, solid insect growth regulators are disclosed. Processes for producing such liquid compositions and uses thereof in animal feeds are also disclosed.
    Type: Application
    Filed: May 10, 2013
    Publication date: May 7, 2015
    Inventor: Bruce Moechnig
  • Publication number: 20150119462
    Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.
    Type: Application
    Filed: December 1, 2014
    Publication date: April 30, 2015
    Inventors: Charles N. SERHAN, Rong YANG
  • Publication number: 20150119423
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of local pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of moderate to severe pain, neuropathic pain, post herpetic neuralgia and rheumatic pains.
    Type: Application
    Filed: May 18, 2013
    Publication date: April 30, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150111749
    Abstract: Methods and compositions for controlling plant pests, particularly weeds and/or plant phytopathogens using sarmentine and/or analogs thereof are disclosed.
    Type: Application
    Filed: December 31, 2014
    Publication date: April 23, 2015
    Inventors: Huazhang Huang, Ratnakar Asolkar
  • Publication number: 20150111966
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, bipolar depression, stress, cancer pain, and lower back pain.
    Type: Application
    Filed: February 10, 2013
    Publication date: April 23, 2015
    Inventor: Mahesh KANDULA
  • Patent number: 9012501
    Abstract: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft to gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: April 21, 2015
    Assignee: Chrysalis Pharma AG
    Inventors: Jean-Pierre Sachetto, Roly Bufton, Thomas Buser